To allow for a comparison of the investigated cohort with previously described cohorts of metastatic melanoma patients treated with different sequencing regimens of BRAF/MEK inhibitors and CPI, we used Cox regression analysis to identify clinical and biological factors affecting survival upon melanoma treatment. Here, BRAF is linked to metastatic melanoma.